Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on deep, unbiased proteomics, and the SEER news feed reflects that focus. Company press releases highlight how Seer’s Proteograph Product Suite—combining proprietary engineered nanoparticles, automation instrumentation, consumables, and analytical software—is being used in large-scale and translational research across cardiovascular disease, oncology, aging biology, and other areas of human health.
Investors and researchers following SEER news will find regular updates on financial results, platform launches, and scientific validation. Seer’s quarterly earnings announcements describe revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects, along with commentary on adoption of its platform and the growth of third-party publications and preprints that use its technology.
The news stream also covers Seer’s presence at major scientific and investor conferences. Releases detail presentations at meetings such as the Human Proteome Organization World Congress and the American Society of Human Genetics, where independent and collaborative studies showcase applications of the Proteograph platform in deep plasma proteomics, biomarker discovery, proteogenomics, and multi-omic precision medicine research. Other items include participation in healthcare and life sciences investor conferences, as well as board and governance updates.
For those tracking how proteomics technologies are being deployed in population-scale and translational studies, Seer’s news provides insight into collaborations, such as population-scale proteomics projects and genome-wide association studies using the Proteograph platform. Bookmarking the SEER news page offers a centralized view of Seer’s financial disclosures, scientific milestones, and corporate developments as reported in its official communications.
Seer, a life sciences company, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:40 p.m. PT. The event will feature a fireside chat with Seer's management, and interested parties can access a live webcast on the investor section of Seer's website. Seer's Proteograph Product Suite offers innovative solutions for deep proteomic analysis, designed for efficiency and ease of use. This platform is intended for research purposes only and is not for diagnostic procedures.
Seer Inc. (NASDAQ: SEER) will report its Q1 2022 financial results on May 4, 2022, followed by a conference call at 2:00 p.m. Pacific Time. The company is known for its innovative Proteograph Product Suite, designed for advanced proteomic analysis. This technology allows for deep, unbiased research capabilities, making it accessible to laboratories worldwide. The company emphasizes its focus on research use only, with no current diagnostic applications.
Seer Appoints New Chief Commercial Officer
Seer, Inc. (Nasdaq: SEER) announced the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Thomas joins Seer with over 20 years of sales experience in the life sciences sector, previously serving at Singular Genomics and Illumina. CEO Omid Farokhzad expressed enthusiasm for Thomas's leadership as the company accelerates its commercial efforts following the launch of the Proteograph Product Suite, designed to enhance access to proteomic analysis.
Seer, Inc. (Nasdaq: SEER) announced a study published in PNAS showcasing their Proteograph Product Suite's superior performance in deep proteomics. The study revealed significant advancements in precision and throughput, achieving a median depth of coverage improvement of tenfold, 2x precision enhancement, and 2.5x more protein identifications compared to conventional methods. These findings establish the Proteograph as a leading tool for unbiased proteomics studies, vital for understanding the proteome's role in precision medicine.
Seer, Inc. (Nasdaq: SEER) reported a significant increase in revenue for the full year 2021, totaling $6.6 million, driven by the successful launch of the Proteograph Product Suite. The fourth quarter alone saw revenue of $3.1 million, up from $336 thousand in Q4 2020. However, the company faced a net loss of $19.7 million in the fourth quarter and $71.2 million for the full year. For 2022, Seer anticipates revenue of $14.0 million to $16.0 million while increasing investments in commercial and R&D activities.
Seer, a life sciences company specializing in proteomics, has announced its virtual participation in the Cowen 42nd Annual Health Care Conference scheduled for March 8, 2022. The company's management will engage in a fireside chat at 11:50 a.m. Pacific Time. Interested investors can access a live webcast on Seer’s investor website, with an archived replay available afterward. Seer’s Proteograph Product Suite enables deep proteomic analysis efficiently and is designed for research use only, aiming to enhance laboratory capabilities.
Seer Inc. (NASDAQ: SEER) will release its financial results for Q4 and full year 2021 on February 28, 2022, after market close. A conference call with management will follow at 1:30 PM PT / 4:30 PM ET, available via a live webcast on Seer's investor website. Seer specializes in proteomics, offering the Proteograph Product Suite, which comprises engineered nanoparticles and software for comprehensive proteomic analysis. The suite aims to enhance research efficiency, though it is not intended for diagnostic use.
Seer Inc. (NASDAQ: SEER) has officially launched the Proteograph Product Suite, which promises revolutionary advancements in proteomics, akin to next-generation sequencing in genomics. The suite employs proprietary engineered nanoparticles, enabling rapid and unbiased proteomics analysis. Seer has secured multiple orders for this product and initiated its Centers of Excellence program, partnering with leading service providers globally to facilitate the technology's adoption. Key partners include Biodesix and Discovery Life Sciences, enhancing service accessibility in major geographies.
Seer Inc. (NASDAQ: SEER), SCIEX, and Discovery Life Sciences have formed the Proteogenomics Consortium to enhance proteomics analysis for genomics research. This collaboration aims to analyze over 1 billion peptides annually, enabling the discovery of new protein variants and biomarkers. The Proteograph Product Suite and SCIEX ZenoTOF 7600 will provide deep, unbiased proteomics capabilities. The consortium is positioned to accelerate research in human health and disease, significantly expanding proteomic studies across various cohorts.
Seer Inc. (NASDAQ: SEER) has announced the broad commercial release of its Proteograph Product Suite, which facilitates unbiased and rapid proteomics. The product suite has garnered multiple orders and includes engineered nanoparticles, automated instrumentation, and software for deep proteomics studies. Seer's new Centers of Excellence program aims to accelerate the adoption of this technology by partnering with leading service providers worldwide. These developments position Seer as a leader in innovative proteomics solutions, enhancing research capabilities across various regions.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
